NIH-funded research R01 grant

Understanding how IL-18 affects atopic dermatitis

Official title: Defining the role of IL-18 in atopic dermatitis

Funded at Washington University · NIH-11064050 · Data updated 2026-11-12

This study is looking at how a substance called IL-18 affects atopic dermatitis, a skin condition that causes itching and inflammation, to help find new ways to treat it.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWashington University
NIH-funded
Lab location1 site (Saint Louis, United States)
Project startApril 10, 2023
Project endMarch 31, 2028
Funding year2025
Award (this year)$809,010
NIH project number5R01AI176660-03
Project IDNIH-11064050 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals of all ages suffering from moderate to severe atopic dermatitis.

Less likely to help

Patients with mild atopic dermatitis or those not experiencing significant allergic inflammation may not benefit from this research.

What this research studies

This research investigates the role of interleukin-18 (IL-18) in atopic dermatitis, a common skin condition characterized by chronic inflammation and itching. The study aims to understand how IL-18 influences the activation of immune cells, particularly basophils and group 2 innate lymphoid cells (ILC2s), which are known to produce type 2 cytokines that drive allergic responses. By analyzing skin samples and using advanced techniques like single-cell RNA sequencing, researchers hope to uncover the mechanisms by which IL-18 contributes to the symptoms of atopic dermatitis. This could lead to new therapeutic strategies targeting IL-18 to alleviate the condition.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that specifically target IL-18, potentially reducing symptoms and improving the quality of life for patients with atopic dermatitis.

How similar studies have gone: Previous research has shown promising results in targeting type 2 cytokines for atopic dermatitis, suggesting that exploring IL-18 could be a valuable and novel approach.

Where this research is happening

  • Washington University
    Saint Louis, United States
    Active

Researchers

  • Principal investigator: Van Dyken, Steven — Washington University
  • Study coordinator: Van Dyken, Steven

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.